ProCE Banner Activity

First-in-Human Phase I Study of BCMA x CD3 Bispecific Antibody REGN5458 in Patients With R/R MM

Slideset Download
Conference Coverage
In this early study, anti-BCMA bispecific antibody REGN5458 showed promising efficacy and safety in heavily pretreated patients with R/R MM.

Released: December 15, 2020

Expiration: December 14, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology